Literature DB >> 17063372

Changes in the natural history of renal cancer: comparison of Estonian data from the periods 1986-1988 and 1996-1998.

Peeter Padrik1, Ulle Kirsimägi, Hele Everaus.   

Abstract

To explain considerable increase in survival of renal cancer patients in Estonia during last decades, we compared the stage distribution, diagnostic and treatment methods for the patient groups diagnosed in the periods 1986-1988 and 1996-1998. A significant difference in stage distribution was detected with an increase for stages I-II and a decrease for stages III-IV in 1996-1998. There was a shift in primary diagnostic methods from intravenous urography and angiography to ultrasonography and computed tomography. In multivariate analysis the independent prognostic factors for overall survival were age, stage, and operation status. In conclusion, the increase in the survival of renal cancer patients has been due to the larger number of cases with the earlier stage, which is associated with the application of ultrasonography and computed tomography. Another factor for better survival was the higher operation rate among patients with stage IV disease, a possible factor was the change in operation techniques.

Entities:  

Mesh:

Year:  2006        PMID: 17063372     DOI: 10.1007/s11255-006-9110-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  8 in total

Review 1.  The changing natural history of renal cell carcinoma.

Authors:  A J Pantuck; A Zisman; A S Belldegrun
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

2.  Guidelines on renal cell cancer.

Authors:  G Mickisch; J Carballido; S Hellsten; H Schulze; H Mensink
Journal:  Eur Urol       Date:  2001-09       Impact factor: 20.096

3.  Global increases in kidney cancer incidence, 1973-1992.

Authors:  A Mathew; S S Devesa; J F Fraumeni; W-H Chow
Journal:  Eur J Cancer Prev       Date:  2002-04       Impact factor: 2.497

4.  Improvement in survival of patients with cancer of the kidney in Europe. EUROCARE Working Group.

Authors:  R A Damhuis; W J Kirkels
Journal:  Eur J Cancer       Date:  1998-12       Impact factor: 9.162

Review 5.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

Authors:  John S Lam; Oleg Shvarts; John T Leppert; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

6.  EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

Authors:  M Sant; T Aareleid; F Berrino; M Bielska Lasota; P M Carli; J Faivre; P Grosclaude; G Hédelin; T Matsuda; H Møller; T Möller; A Verdecchia; R Capocaccia; G Gatta; A Micheli; M Santaquilani; P Roazzi; D Lisi
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

7.  Trends in cancer patient survival in Estonia before and after the transition from a Soviet republic to an open-market economy.

Authors:  Tiiu Aareleid; Hermann Brenner
Journal:  Int J Cancer       Date:  2002-11-01       Impact factor: 7.396

8.  Cancer survival in Estonia from 1978 to 1987.

Authors:  T Aareleid; M Rahu
Journal:  Cancer       Date:  1991-11-01       Impact factor: 6.860

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.